CO2019005247A2 - Composición farmacéutica para evitar la adicción a opioides - Google Patents

Composición farmacéutica para evitar la adicción a opioides

Info

Publication number
CO2019005247A2
CO2019005247A2 CONC2019/0005247A CO2019005247A CO2019005247A2 CO 2019005247 A2 CO2019005247 A2 CO 2019005247A2 CO 2019005247 A CO2019005247 A CO 2019005247A CO 2019005247 A2 CO2019005247 A2 CO 2019005247A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
patient
opioid addiction
prevent opioid
composition
Prior art date
Application number
CONC2019/0005247A
Other languages
English (en)
Inventor
John Davis
Catherine Stehman-Breen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2019005247A2 publication Critical patent/CO2019005247A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe una composición farmacéutica para evitar la adicción a los opioides en un paciente. La composición se puede utilizar en un paciente que sufre de lumbalgia (LBP) moderada a severa. La composición es útil en un paciente diagnosticado con dolor lumbar y comprende una cantidad terapéuticamente eficaz de un anticuerpo que se une específicamente al factor de crecimiento nervioso (NGF) o un fragmento de unión a antígeno del mismo; y se usa en ausencia de un opioide para aliviar el dolor y evitar la adicción a los opioides en un paciente.
CONC2019/0005247A 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides CO2019005247A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (1)

Publication Number Publication Date
CO2019005247A2 true CO2019005247A2 (es) 2019-05-31

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005247A CO2019005247A2 (es) 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides

Country Status (16)

Country Link
US (2) US10736961B2 (es)
EP (1) EP3548082B1 (es)
JP (1) JP7071975B2 (es)
KR (1) KR20190090820A (es)
CN (1) CN110072549A (es)
AU (1) AU2017366870A1 (es)
BR (1) BR112019010331A2 (es)
CA (1) CA3045116A1 (es)
CL (1) CL2019001385A1 (es)
CO (1) CO2019005247A2 (es)
EA (1) EA201991283A9 (es)
IL (1) IL266640B (es)
MA (2) MA46951A (es)
MX (1) MX2019006013A (es)
PH (1) PH12019501087A1 (es)
WO (1) WO2018102294A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11472870B2 (en) 2018-08-10 2022-10-18 Regeneron Pharmaceuticals, Inc. Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2572729A3 (en) * 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
EA028945B1 (ru) 2010-10-06 2018-01-31 Ридженерон Фармасьютикалз, Инк. СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)

Also Published As

Publication number Publication date
CL2019001385A1 (es) 2019-07-26
US20180147280A1 (en) 2018-05-31
MA45890B2 (fr) 2022-10-31
BR112019010331A2 (pt) 2019-10-22
CN110072549A (zh) 2019-07-30
EA201991283A9 (ru) 2019-11-27
JP2019535716A (ja) 2019-12-12
MA46951A (fr) 2019-10-09
JP7071975B2 (ja) 2022-05-19
EP3548082A1 (en) 2019-10-09
CA3045116A1 (en) 2018-06-07
IL266640A (en) 2019-07-31
WO2018102294A1 (en) 2018-06-07
IL266640B (en) 2022-09-01
PH12019501087A1 (en) 2019-08-19
US11491222B2 (en) 2022-11-08
EA201991283A1 (ru) 2019-09-30
MA45890A1 (fr) 2020-02-28
US10736961B2 (en) 2020-08-11
US20210060159A1 (en) 2021-03-04
AU2017366870A1 (en) 2019-06-06
EP3548082B1 (en) 2024-05-15
KR20190090820A (ko) 2019-08-02
MX2019006013A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
CO2019005247A2 (es) Composición farmacéutica para evitar la adicción a opioides
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
CR20180097A (es) Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
CO6280488A2 (es) Combinacion farmaceutica
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112015024625A2 (pt) composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
CO2021017688A2 (es) Anticuerpo biespecífico contra α-syn/igf1r y uso del mismo
CO2019002477A2 (es) Anticuerpo para tratar enfermedades autoinmunes
BR112017004590A2 (pt) métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l
EA202190504A1 (ru) Способы лечения псориаза
CU20200015A7 (es) Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha